|
AstraZeneca and Lilly expand immuno-oncology research collaboration with new combinations
|
22 October 2015 |
|
New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis
|
01 October 2015 |
|
AstraZeneca purchases US biologics manufacturing facility to support growing pipeline
|
11 September 2015 |
|
AstraZeneca to invest £11.5 million in new clinical oncology bioinformatics collaboration with The University of Manchester
|
08 September 2015 |
|
US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack
|
04 September 2015 |
|
AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab
|
01 September 2015 |
|
AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial
|
24 August 2015 |
|
AstraZeneca and Heptares Therapeutics enter agreement to develop novel immuno-oncology treatments
|
07 August 2015 |
|
MedImmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer
|
05 August 2015 |
|
AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases
|
03 August 2015 |